Harvard Bioscience, Inc.
HBIO · Price history
Price at last available close
$8.42
+$0.46 (+5.78%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Harvard Bioscience, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems.
How they make money
Harvard Bioscience develops, manufactures, and sells specialized technologies and instruments that support life science research, drug discovery, and preclinical testing. The company generates revenue through direct sales and distribution channels, providing hardware and services to pharmaceutical companies, biotechnology firms, and academic institutions globally.
Products & services
The company provides translational research tools including syringe pumps, electrophysiology equipment, behavioral research systems, and bioproduction instruments used in drug and therapy development.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer types
Customer concentration
No single customer accounted for more than 10% of total revenues in 2025 or 2024.
Suppliers, materials & equipment
- Unnamed third-party manufacturers — The company utilizes third-party manufacturers for certain products, with sales of these distributed products accounting for approximately 13% of total revenues in 2025.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
20
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
26
Poor
Financial Strength
40
Business Quality / Moat
33
Management
13
Growth Quality
21
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
28
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
34/100
Building Historical Record
Model Score 34/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for HBIO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can HBIO maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is HBIO's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is HBIO's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for HBIO to reach sustainable profitability?
- •What future growth or profitability would be needed to justify HBIO's current valuation?
Essential Investment Snapshot
Wall Street Score
20
Opportunity Score
28
Market Cap
$38.3M
P/E Ratio
-3.4
EPS
$-2.33
52-Week High
$9.40
52-Week Low
$3.76
Beta
1.53
Analyst Target
$38.00
Shares Outstanding
4.4M
Total Revenue
$87.8M
Total Debt
$44.2M
Dividend
No current dividend
Liquidation Value / Share
$1.67
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for HBIO
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-0.1x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on HBIO.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Established brand history dating back to 1901.
- +Broad global customer base across academic and commercial sectors.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Instruments & Supplies industry.
- −Dependence on third-party distribution and manufacturing.
- −Exposure to international market and currency fluctuations.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
20
Sep 28, 2026
Change
Unchanged
Current Score
20
Oct 1, 2026
Category Changes
HBIO score was unchanged.
Projected Score
Projected Score
19
Projected Change
-0.8 points
Preliminary comparable-period financial changes suggest decline of approximately 0.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$8.42
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $87.8M | $86.5M | $94.1M | $112.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $36.7M | $40.7M | $39.4M | $46.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $51.1M | $45.9M | $54.8M | $66.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $9.1M | $8.8M | $10.4M | $11.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $38.1M | $37.0M | $43.7M | $46.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $50.0M | $46.5M | $61.0M | $64.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$939K | -$46.5M | -$1.5M | $8.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $1.0M | -$629K | -$6.2M | $1.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $3.4M | $4.9M | $3.2M | $3.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$10.5M | -$57.4M | -$11.7M | -$2.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$129K | -$686K | $740K | $859K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$10.4M | -$56.7M | -$12.4M | -$3.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-2.33 | $-12.80 | $-2.80 | $-0.81 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 4.53M | 4.44M | 4.35M | 4.24M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 4.53M | 4.44M | 4.35M | 4.24M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$22.7M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.64
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+2.1%
Cash Change
-12.6%
Margin Change
-1.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth. Pressure indicators included cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 11.1%. EPS increased 24.3%. Cash declined 12.6%. Total debt increased 2.1%. Net income margin declined by 1.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Instruments & SuppliesRumor Mill · HBIO
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial